Document is current
Any future updates will be listed below
-
Authors
Mange, Kevin C.
Serrano, Daniel
Hassan, Mariam
Nevoret, Marie-Laure
Yuen, Dayton W.
McManus, Shauna
Podger, Lauren
Barnes, Bryant
Daley, Charles L.
-
Funding
Funding for this research was provided by:
Insmed (Insmed)
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 21 August 2025
First Online: 16 October 2025
Declarations
:
: The studies were conducted in accordance with the Declaration of Helsinki. Local institutional review boards or independent ethics committees approved the study protocols. All patients provided written or electronic informed consent.
: Not applicable.
: Part of this article has been presented at the ISPOR 2024 Conference, Atlanta, GA, May 5-8, 2024.
: KCM, MH, MN, and DWY are employees and shareholders of Insmed Incorporated. DS, BB, SM, and LP were employees of OPEN Health Group at the time of study, which was funded by Insmed Incorporated. CLD reports grant support, advisory board fees, and consulting fees from Insmed Incorporated. CLD also reports grant support from AN2 Therapeutics, Bugworks, Paratek Pharmaceuticals, Juvabis; advisory board work with AN2 Therapeutics, AstraZeneca, Cepheid, Galapagos, Hyfe, MannKind, Matinas Biopharma, NobHill, Spero Therapeutics, Zambon; consulting with Genentech, Pfizer; data monitoring committee work with Otsuka Pharmaceutical, Bill and Melinda Gates Foundation.
